Bruker (BRKR) Tops Q2 EPS by 15c

Bruker (NASDAQ: BRKR) reported Q2 EPS of $0.21, $0.15 better than the analyst estimate of $0.06. Revenue for the quarter came in at $424.6 million versus the consensus estimate of $390.92 million.

Fiscal Year 2020 (FY 2020) Guidance Remains Suspended

Bruker’s FY 2020 financial guidance remains suspended. While Bruker continues to expect the pandemic to have a negative year-over-year impact on the Company’s third quarter 2020 financial results, Bruker anticipates a sequential improvement in financial results from the second quarter to the third quarter of 2020.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• Sun Communities completes $1.03B sale of Park Holidays to Aermont
• Aytu BioScience (AYTU) Tops Q4 EPS by 28c